Brian Gastman, M.D.
Staff

Brian Gastman, M.D.

Staff

  • Department of Immunology
  • Lerner Research Institute (NB30)
  • The Cleveland Clinic Foundation
  • 9500 Euclid Avenue
  • Cleveland, Ohio 44195
  • (216) 444-2501
  • (216) 444-9329
  • gastmab@ccf.org

Research interest

Tumor Immunology - Studying how cancers actively induce suppressor cells as part of immune evasion.

Cancer Therapy Resistance - Studying how oncogenes known to have anti-apoptotic properties have in addition anti-senescent functions rendering tumors chemotherapy resistant.

Current program

  • Tumor Immunology - We are developing not only animal models to better understand this process, but also as a basis to investigate novel inhibitory strategies to enhance current immunotherapeutic approaches. Tumor secreted factors also appear to be an important part of this process, and thus identifying them and creating reagents for study and inhibition is also part of our investigations.
  • Cancer Therapy Resistance - We are moving toward a better understanding of these oncogenes from a molecular and biochemical standpoint as they inhibit chemotherapy induced senescence. Our goal is to identify new molecules involved in this process and new inhibitors of these oncogenes that will ultimately have clinical utility.

Investigators

  • Brian Gastman, MD - PI
  • Lukas Pfannenstiel, Ph.D. - Post Doctoral Fellow
  • Mathew Lesniewski, Ph.D. - Post Doctoral Fellow
  • Abeba Demelash, Ph.D. - Post Doctoral Fellow

Collaborators

  • Vince Tuohy, Ph.D., Dept. Immunology, CCF
  • Hannah Rabinowich, Ph.D. - University of Pittsburgh
  • Koji Tamada, MD - University of Maryland
  • Abeba Demelash Ph.D.
  • Postdoctoral Fellow
  • Location:NE6-251
  • demelaa@ccf.org
  • Lukas Pfannenstiel PhD
  • Postdoctoral Research Fellow
  • Location:NE6-251
  • pfannel@ccf.org
  • (216) 444-0202

Publications

Moche JA, Chopra K, Gastman B. Vascularized Free Fibula for Cervical Spine Reconstruction following Complicated Retropharyngeal Abscess. Otolarygology Head and Neck Surgery ahead of publication.

Gastman B. Reply: excising value at a marginal cost: rethinking the management of Basal cell carcinoma. Plast Reconstr Surg. 2011 May;127(5):2137.

Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI.  Human {gamma}{delta} T lymphocytes induce robust NK cell mediated antitumor cytotoxicity through CD137 engagement.  Blood. Sep 9;116(10):1726-33. 2010

Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between anti-apoptotic Bcl-2 members and Bim.  J Biol Chem. 2010 Jul 16;285(29):22473-83.

Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, Lin W, Li G, Burch E, Tan M, Hertzano R, Chapoval AI, Tamada K, Gastman BR, Schulze DH, Strome SE.    CD137 promotes proliferation and survival of human B cells. J Immunol. Jan 15;184(2):787-95, 2010.

Gulleh Y, Silverman R, Goldebrg N, Gastman BR. What is the best surgical margin for a Basal cell carcinoma: a meta analysis of the literature. Plast Reconstr Surg. 2010 Oct;126(4):1222-31

Sumer B, Gastman BR, Haughey BH, Nussenbam B. Microvascular Reconstruction of the Laryngopharynx with Intent of Laryngeal Conservation. Archives of Otolaryngology, 135(8):801-6, 2009.

Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, Pauza CD, Strome SE, Chapoval A. Isopentenyl pyrophosphate activated CD56+ ?d T lymphocytes display potent anti-tumor activity towards human squamous cell carcinoma.  Clinical Cancer Research, 14 ( 13 ): 4232-40, 2008 .

Montes CL,  Chapoval A,  Nelson J,  Orhue V,  Zhang X, Schulze DH, Strome  SE, Gastman BR. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion.  Cancer Research, 68 ( 3 ): 870-9, 2008.